AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Amgen

Status and phase: Completed; Phase 3

Conditions: Prostate Cancer

Treatments: Drug: Placebo; Drug: AMG 162

Study type: Interventional

Funder types: Industry

Identifiers

NCT00089674

20040138

HALT Prostate Cancer

Details and patient eligibility

About

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Enrollment: 1,468 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Other criteria also apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,468 participants in 2 patient groups, including a placebo group

AMG 162

Experimental group

Treatment:

Drug: AMG 162

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo